Prakt. lékáren. 2008; 4(6): 276-280

TRADITIONAL OR CONJUGATED VACCINES AGAINST MENINGOCOCCAL INFECTIONS?

RNDr. Marek Petráš
Specialista v oboru vakcinologie, Praha

Currently, not only original polysaccharide vaccines but also new conjugated vaccines are available for use against meningococcal infections. Since both types have their place in the market, the question is raised as to when to use which vaccine. A major selection criterion is the required reliability of protection after a particular vaccine, which is largely dependent upon the age of the person vaccinated.

Keywords: Key words: vaccination, meningococcus, vaccines.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráš M. TRADITIONAL OR CONJUGATED VACCINES AGAINST MENINGOCOCCAL INFECTIONS? Praktické lékárenství. 2008;4(6):276-280.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato Neto V, Finger H, Gotschlich EC, et al. Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children. Rev Inst Med Trop Sao Paulo 1974; 16: 149-153. Go to PubMed...
    2. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282: 417-420. Go to original source... Go to PubMed...
    3. Biselli R, Casapollo I, D'Amelio R, et al. Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand J Immunol 1993; 37: 644-650. Go to original source... Go to PubMed...
    4. Borrow R, Richmond P, Kaczmarski EB, et al. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine. FEMS Immunol Med Microbiol 2000; 28: 79-85. Go to original source... Go to PubMed...
    5. Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 2001; 19: 2924-2931. Go to original source... Go to PubMed...
    6. Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19: 144-150. Go to original source... Go to PubMed...
    7. Campbell H, N Andrews, M Ramsay, E Miller; Immunisation Department, HPA Centre for Infections; R Mallard, R Borrow, S Gray. Meningococcal Reference Unit, Manchester Medical Microbiology Partnership., ,Impact of the meningococcal c conjugate vaccination programme in England"; summary surveillance report from the immunisation department health protection agency centre for infections, june 2006.
    8. Ceesay SJ, Allen SJ, Menon A, et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993; 167: 1212-1216. Go to original source... Go to PubMed...
    9. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285: 177-181. Go to original source... Go to PubMed...
    10. De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada. Bull WHO 1996; 74: 407-411.
    11. English M, MacLennan JM, Bowen-Morris JM, et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2000; 19: 1232-1238. Go to original source... Go to PubMed...
    12. Espin Rios I, Garcia-Fulgueiras A, Navarro Alonso JA, et al. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine 2000; 18: 2656-2660. Go to original source... Go to PubMed...
    13. Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996; 174: 1360-1363. Go to original source... Go to PubMed...
    14. Gheesling LL, Carlone GM, Pais LB, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzymelinked immunosorbent assay. J Clin Microbiol 1994; 32: 1475-1482. Go to original source... Go to PubMed...
    15. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-1970. Bull WHO 1971; 45: 279-282. Go to PubMed...
    16. Gold R, Lepow ML, Goldschneider I, et al. Immune response of human infants to polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 1977; 136: suppl S31-5. Go to original source... Go to PubMed...
    17. Gold R, Lepow ML, Goldschneider I, et al. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140: 690-697. Go to original source... Go to PubMed...
    18. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129: 1307-1326. Go to original source... Go to PubMed...
    19. Goldschneider I, Lepow ML, Gotschlich EC, et al. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis 1973; 128: 769-776. Go to original source... Go to PubMed...
    20. Goldschneider I, Lepow ML, Gotschlich EC. Immunogenicity of the group A and group C meningococcal polysaccharides in children. J Infect Dis 1972; 125: 509-519. Go to original source... Go to PubMed...
    21. Granoff DM, Maslanka SE, Carlone, et al. A modified enzymelinked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998; 5: 479-485. Go to original source... Go to PubMed...
    22. Käyhty H, Karanko V, Peltola H, et al. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis 1980; 142: 861-868. Go to original source... Go to PubMed...
    23. Koeberling O, Seubert A, Granoff DM. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor h-binding protein and genetically attenuated endotoxin. J Infect Dis. 2008 Jul 15; 198(2): 262-270. Go to original source... Go to PubMed...
    24. LCDC. Guidelines for control of meningococcal disease. Canadian Consensus Conference on meningococcal disease. Can Med Assoc J 1994; 150: 1825-1839.
    25. Lepow ML, Goldschneider I, Gold R, et al. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977; 60: 673-680. Go to original source... Go to PubMed...
    26. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 1996; 275: 1499-1503. Go to original source... Go to PubMed...
    27. MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998; 280: 1685-1689. Go to original source... Go to PubMed...
    28. MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001; 183: 97-104. Go to original source... Go to PubMed...
    29. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000; 283: 2795-2801. Go to original source... Go to PubMed...
    30. Maslanka SE, Gheesling LL, Libutti DE, et al. The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4: 156-167. Go to original source... Go to PubMed...
    31. Maslanka SE, Tappero JW, Plikaytis BD, et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from. Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998; 66: 2453-2459. Go to original source... Go to PubMed...
    32. Mehlhorn AJ, Balcer HE, Sucher BJ. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine. Ann Pharmacother. 2006 Apr; 40(4): 666-673. Epub 2006 Mar 7. Review. Go to original source... Go to PubMed...
    33. Mitchell LA, Ochnio JJ, Glover C, et al. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. J Infect Dis 1996; 173: 1009-1013. Go to original source... Go to PubMed...
    34. National Advisory Committee on Immunization. Meningococcal vaccine. In: Canadian immunization guide. 5th edition. Ottawa, Ont.: Health Canada, 1998: 125-129. (Minister of Public Works and Government Services Canada, Cat. No. H49-8/1998E.)
    35. Peltola H, Käyhty H, Kuronen T, et al. Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide. J Pediatr 1978; 92: 818-822. Go to original source... Go to PubMed...
    36. Peltola H. Meningococcal vaccines. Current status and future possibilities. Drugs 1998; 55: 347-366. Go to original source... Go to PubMed...
    37. Pinner RW, Onyango F, Perkins BA et al. The Kenya/Centers for Disease Control Meningitis Study Group. Epidemic meningococcal disease in Nairobi, Kenya, 1989. J Infect Dis 1992; 166: 359-364. Go to original source... Go to PubMed...
    38. Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis. 1995 Mar; 4(1): 13-28. Review.
    39. Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-196. Go to original source... Go to PubMed...
    40. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2: 114-118. Go to original source... Go to PubMed...
    41. Rosenstein N, Levine O, Taylor JP, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998; 279: 435-439. Go to original source... Go to PubMed...
    42. Salleras L, Dominguez A, Prats G. Control of serogroup C meningococcal meningitis by mass vaccination in Catalonia (Spain). Vaccine 1999; 17(Suppl 3): S56-60. Go to original source... Go to PubMed...
    43. Sierra, G. V. G., H. C. C. Campa, I. L. Garcia, P. F. Sotolongo, P. L. Izquierdo, N. M. Valcarcel, G. V. Casanueva, M. S. Baro, C.F. Leguen, C. R. Rodriguez, and M. H. Terry. 1991. Efficacy evaluation of the Cuban vaccine VA-MENGOC-BCR against disease caused by serogroup B Neisseria meningitidis, p. 129-134. In M. Atchtman, et al. (ed.), Neisseria 1990. Walter de Gruyter, Berlin. Go to original source...
    44. Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, Borkowski A, Yu LM, Moxon ER, Pollard AJ. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006 Dec 1; 43(11): 1387-1394. Go to original source... Go to PubMed...
    45. Taunay AE, de Glavao PA, de Morais JA, et al. Disease prevention by meningococcal serogroup C polysaccharide vaccines in preschool children: results after 11 months in Sao Paulo, Brazil. Pediatr Res 1974; 8: 429. Go to original source...
    46. Tsai TF, Borrow R, Gnehm HE, Vaudaux B, Heininger U, Desgrandchamps D, Aebi C, Balmer P, Pedersen RD, Fritzell B, Siegrist CA. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin Vaccine Immunol. 2006 Aug; 13(8): 854-861. Go to original source... Go to PubMed...
    47. Twumasi PA Jr, Kumah S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171: 632-638. Go to original source... Go to PubMed...
    48. Van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995 Mar; 13(4): 401-407. Go to original source... Go to PubMed...
    49. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994; 169: 847-852. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.